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Introduction
Cancer is one of the leading causes of death worldwide 
with an estimated 12.6 million people diagnosed in 2008, 
accounting for approximately 7.6 million deaths glob-
ally.1 Cancer prognosis would improve with better thera-
peutic regimens, particularly when tumours cannot be 
managed by surgical resection alone and require subse-
quent chemo- or radiotherapy. The majority of current 
models for therapeutic and pharmacological investiga-
tions are carried out in either two-dimensional (2D) 
reductionist in vitro cell culture or severe combined 
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immunodeficient (SCID) animal models. It is, however, 
becoming increasingly apparent that microenvironmental 
factors play an important role in controlling both the pro-
gression of cancer and the chemotherapeutic response to 
treatment.2 Although highly useful, 2D in vitro cell mod-
els lack the sophistication of cellular orientation and cell–
matrix interactions, while animal models often overlook 
host factors that are typically involved in disease progres-
sion such as the immune system.3 Both types of investiga-
tions are routinely used by pharmaceutical companies, but 
efficiency of drug discovery and clinical translation 
remain suboptimal. For example, this holds true for the 
family of Endothelin A receptor antagonists, for example, 
atrasentan. Despite encouraging preclinical data, the 
agents failed to demonstrate a benefit in clinical trials and 
therefore have not progressed to the clinic.4 To address the 
gap between 2D culture systems and in vivo models, 
three-dimensional (3D) cell culture systems such as mul-
ticellular tumour spheroids and scaffold-based approaches 
have been used as a bridge to further our understanding of 
cancer biology, particularly how the cells may respond to 
treatment in a 3D environment. Of the available 3D in 
vitro models, spheroid assays are widely used for thera-
peutic testing;5 however, they are inherently limited by 
their size (400–600 µm) resulting from nutrient and O2 
deficiency. Spheroids develop a necrotic core surrounded 
by a rim of viable cells (100–300 µm) in the periphery.6 
Due to the absence of a matrix, cancer cells have restricted 
mobility, a key parameter in the development of microme-
tastases in vivo. More recent approaches have utilized 
natural or synthetic scaffolds. Natural scaffolds include 
extracellular matrix (ECM) proteins such as collagen, 
laminin or hyaluronic acid.7,8 They are largely malleable 
by cell behaviour, typically as a result of ECM degrading 
proteins such as matrix-metalloproteinases (MMPs). This 
is remarkably helpful for modelling the complex dynamic 
nature of tumours. Natural scaffolds are also appealing 
due to their biocompatibility and orientation that allows 
cell surface receptors such as integrins and discoidin 
domain receptors to interact with natural matrix proteins. 
Hyperhydrated gel systems such as collagen consist of 
cross-linked macromolecular networks of hydrophilic 
polymers.9 However, this hyperhydration (~99% water) is 
not physiologically representative of any tissue in the in 
vivo environment, and ultimately, more biomimetic mod-
els are needed to model tumours accurately. Synthetic 
scaffolds such as polyethylene glycol (PEG) and polygly-
colic acid (PGA) are biodegradable scaffolds that function 
to mimic the macromolecular structures of the ECM.10,11 
Compared to natural scaffolds, they are mechanically 
stiffer and therefore suitable for modelling the dense 
tumour microenvironment. However, they are not without 
their disadvantages, often having to undergo surface mod-
ifications to improve cell attachment, migration and scaf-
fold degradation.12
In this article, we describe for the first time the creation 
and use of a 3D collagen-based multiwell platform for 
therapeutic validation into colorectal cancer. Tissue-
engineered 3D cultures are generated by the RAFT™ 
(Real Architecture For 3D Tissue) technology, a process 
based on the removal of water from hyperhydrated colla-
gen hydrogels.13 This controlled removal of water provides 
a structurally and physiologically relevant matrix. We 
chose colorectal as the demonstrator cancer and used the 
HT29 and HCT116 cancer cell lines to create 3D cultures 
and monitored growth, morphology and response to tar-
geted treatment. The cell lines were chosen for their KRAS 
mutant status – HCT116 mutant and HT29 wild-type.14 
The expression of the epidermal growth factor receptor 
(EGFR) was investigated as a biomarker and compared to 
2D monolayer expression levels. EGFR was targeted for 
treatment using cetuximab, the monoclonal antibody 
raised against the EGFR receptor. These preclinical data 
demonstrate the use of our 3D cultures as a simple, fast 
and consistent model for drug testing. We propose this as a 
suitable in vitro model to help bridge the gap between con-
ventional 2D monolayer studies and complex in vivo ani-
mal models.
Materials and methods
Cell maintenance
The HT29 human colorectal adenocarcinoma cell line and 
the HCT116 human colorectal carcinoma cell lines (both 
from the European Collection of Cell Cultures, Sigma–
Aldrich, Dorset, UK) were used. HT29 and HCT116 cells 
were routinely cultured in 2D monolayers in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 
1 g/L glucose, 10% fetal bovine serum (FBS), 100 units/
mL penicillin and 100 µg/mL streptomycin (all from 
Invitrogen, Paisley, UK) at 37°C in standard cell culture 
conditions (5% CO2/air and 95% humidity).
Preparation of 3D cultures
The 3D cultures were prepared using the RAFT™ 3D cell 
culture system in 96-well plates as detailed by the manufac-
turer’s instructions (TAP Biosystems, Royston, UK). In 
brief, 2.8 mL of Minimal Essential Medium (MEM 10×) 
was added to 22.4 mL of rat-tail collagen type I. This solu-
tion was neutralized by 1.6 mL of the neutralizing solution 
provided, before 1.2 mL of the cell suspension was added 
(1.96 × 106 cells/mL). The collagen–MEM–cell solution 
was mixed gently and aliquoted into the 96-well plate 
(240 µL per well) and placed on a plate heater (37°C) for 
15 min, initiating collagen fibrillogenesis to produce a cell-
populated collagen hydrogel. While still on the heater, bio-
compatible hydrophilic RAFT™ absorbers were placed on 
the hydrogels and left for 15 min (Figure 1). This process 
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removes some interstitial fluid while preserving cell viabil-
ity and creates a more physiological matrix (9.59% ± 0.64% 
collagen as measured by freeze drying to determine the wet 
and dry weight). Fully supplemented medium was added to 
each well, and the plates were placed in the incubator, under 
standard culture conditions.
Cell proliferation and morphology
HT29 and HCT116 cultured in 3D were seeded at a den-
sity of 1.96 × 106 cells/mL per 3D culture. Preliminary 
cell density studies indicated that this was the optimum 
cell density for growth and ease of imaging (data not 
shown). Metabolic activity was assessed over 14 days 
using the alamarBlue® assay according to the manufactur-
ers’ protocol (Invitrogen). AlamarBlue measures the 
chemical reduction of resazurin to resorufin by mitochon-
drial activity and provides an indicator of metabolic activ-
ity. DMEM without phenol red (Invitrogen) was used to 
minimize saturation of the fluorescent dye. In brief, 
100 µL of alamarBlue solution (10% solution in fully sup-
plemented DMEM) was added to each well. The samples 
were incubated for 4 h at 37°C and the solution transferred 
to a black-bottom 96-well plate to obtain a fluorescent 
reading at excitation of 530 nm and emission 620 nm. Cell 
morphology was also monitored in real time by live-cell 
phase-contrast imaging using a Nikon, Eclipse TE300 
microscope.
Immunofluorescence
Cell morphology was confirmed by immunofluorescence. 
The 3D cultures were fixed in 4% paraformaldehyde for 
30 min and washed thoroughly in phosphate-buffered 
saline (PBS) (three washes for 5 min each). The cultures 
were permeabilized with 1% Triton X-100 (TX-100) for 
15 min and again washed thoroughly with PBS. This was 
followed by incubation with an anti-tubulin primary anti-
body solution (Abcam, Cambridge, UK; at 1:200 in a 
blocking solution of PBS containing 1% bovine serum 
albumin (BSA) and 0.2% TX-100) overnight at 4°C. The 
samples were then washed three times in PBS for 5 min 
each and incubated with a Cy3 conjugated secondary anti-
body (Jackson ImmunoResearch, West Grove, PA, USA; 
1:200), Alexa Fluor 488 conjugated Phalloidin (Invitrogen; 
1:40) and 4′,6-diamidino-2-phenylindole (DAPI) diluted 
in the blocking solution for 2.5 h at room temperature. The 
cultures were then washed three times with PBS for 5 min 
each and imaged using an Olympus IX71 Inverted 
Fluorescent Microscope fitted with a Prior z-focus drive.
Gene expression analysis
Gene expression levels of EGFR were measured with one-
step quantitative reverse transcription polymerase chain 
reaction (qRT-PCR) using a LightCycler® system (Roche, 
Hertfordshire, UK). Cells were collected from 3D collagen 
gels by digestion in 100 units/mL collagenase (from 
Clostridium histolyticum) in Tris buffer (Sigma–Aldrich) 
for 2 h. RNA was extracted from cells in either 2D or 3D 
after 3 days in culture using the RNeasy Mini Kit (Qiagen, 
Crawley, UK) according to the manufacturer’s instruc-
tions. Total RNA was quantified using a nanodrop spectro-
photometer measuring at 260/280 nm. All experiments 
were performed in triplicate.
Drug treatment in 2D and 3D
For 2D monolayer experiments, HT29 cells and HCT116 
cells were seeded at a density of 18,000 and 17,000 cells/
cm2, respectively. Cells were allowed to grow overnight 
before being serum-starved for 24 h in serum-free DMEM. 
The 3D cultures were seeded at a density of 20,000 cells 
(1.96 × 106 cells/mL) for both cell lines. The 3D cultures 
were maintained for 6 days before being serum-starved for 
24 h prior to treatment. This was carried out to give the 
cells time to acclimatize to the new environment and for 
cellular aggregates to form. Cellular aggregates in this 
context are defined by the migration and adhesion of can-
cer cells to each other to form cell clusters. Cetuximab 
(Merck, Darmstadt, Germany) was diluted in serum-free 
DMEM over a range of concentrations immediately prior 
Figure 1. A schematic diagram of how 3D cultures are created.
3D: three-dimensional.
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to treatment and incubated for 48 h (2D monolayers) or 
72 h (3D cultures). Controls were treated with serum-free 
DMEM only. Metabolic activity was measured using the 
alamarBlue assay and was considered an indicator of cell 
viability.
Evaluation of cell aggregate size
The surface area of 3D cellular aggregates (n = 10) was 
quantified using measurements based on their circumfer-
ence using the ImageJ software (version 1.46v). The line 
tool was used to trace around the cellular aggregates, and 
the area was calculated using a predetermined scale that 
was set in ImageJ.
Statistical analysis
Data were presented as means and standard deviations of 
each group. Statistical analysis was carried out using a 
one-way analysis of variance (ANOVA) with post hoc 
Dunnett’s test. Significance was accepted at and below 
0.05. Results were shown on occasion as percentages for 
ease of presentation. However, all statistical analyses were 
carried out on the original data.
Results
Cancer cell proliferation and morphology
To assess the metabolic activity of HT29 and HCT116 
cells in 3D culture, the alamarBlue assay was used. Since 
the assay is non-toxic, multiple readings over a timescale 
were measured for each well. Increases in metabolic activ-
ity, taken as an indicator of cell proliferation, and therefore 
increases in cell number were determined over 14 days for 
both cell lines (Figure 2(a)). HT29 cells displayed a steady 
increase in cell number that appeared to plateau at day 14. 
Morphologically, the cellular aggregates appeared to grow 
in size consistently over the 14-day period, in line with the 
proliferation measurements. On the other hand, although 
HCT116 cultures exhibited an overall growth pattern over 
14 days, there was a significant drop in the proliferation 
readings at day 7 indicating a quiescent state. However, 
phase-contrast images of HCT116 cellular aggregates 
showed no reduction or a slower rate of apparent growth 
between day 3 and day 7 (Figure 2(b)); therefore, any state 
of biochemical quiescence did not result in a concomitant 
morphological change.
The morphology of cellular aggregates was further 
determined by immunofluorescent analysis of the cytoskel-
etal proteins tubulin and F-actin. Tubulin is involved in 
regulating microtubule dynamics during cell division, 
while the actin filaments are involved in many processes 
including cell motility and the maintenance of cell junc-
tions.15 Figure 3 demonstrates the different morphological 
phenotypes of cellular aggregates of the two cancer cell 
lines in 3D culture. HT29 cells formed irregularly shaped 
aggregates of cells with a defined expression of F-actin 
visible at cell–cell junctions. HCT116 cell aggregates 
demonstrated a more ‘grape-like’ phenotype with the cells 
apparently forming loose clusters with poor cell–cell adhe-
sion in comparison to HT29 cells.16 Semi-quantitative 
analysis of the phalloidin stain demonstrated a twofold 
increase in fluorescent intensity of HT29 cells in compari-
son to HCT116 cells (data not shown). Expression of tubu-
lin was limited to the outer edges of HT29 aggregates, 
while HCT116 expression was localized to the spindle 
fibres of dividing cells throughout the aggregate.
Over-expression of EGFR in 3D compared to 
2D monolayer cultures
To determine gene expression levels, total EGFR messen-
ger RNA (mRNA) expression was assessed in HT29 and 
HCT116 cells cultured in 2D and in 3D by qRT-PCR. 
EGFR mRNA copy number was standardized to 50,000 
copies of G6PDH to ensure that possible differences in cell 
number did not interfere with expression levels. Analysis 
of EGFR mRNA levels on cells cultured in 2D showed that 
HCT116 cells expressed double the EGFR level of the 
HT29 cells (Figure 4). This difference was illustrated fur-
ther in 3D cultures cultured for 3 days, as EGFR expres-
sion was significantly upregulated in comparison to 2D 
monolayers. HT29 3D cultures expressed roughly twice 
the levels of EGFR in comparison to their monolayer 
counterparts (p < 0.05). Similarly, EGFR gene expression 
in HCT116 3D cultures was also increased approximately 
threefold in comparison to 2D (p < 0.01).
Inhibitory effect of cetuximab on 2D monolayer 
and 3D cultures
To determine the cytotoxicity of cetuximab, HT29 and 
HCT116 cells cultured in 2D and in 3D were treated for 48 
and 72 h, respectively, and growth inhibition was assessed by 
the alamarBlue assay. In 2D monolayers, a concentration of 
0.34 nM of cetuximab in HT29 cells resulted in a 60% reduc-
tion in proliferation in comparison to untreated controls 
(p < 0.001), while HCT116 cells appeared to be non- 
responsive (Figure 5(a)). Interestingly, at higher concentra-
tions, cetuximab appeared to stimulate the growth of 
HCT116 cells; however, this was not statistically significant. 
Cetuximab was less effective in 3D cultures demonstrating a 
40% reduction in HT29 proliferation at 3.4 nM; while again, 
HCT116 cultures were non-responsive (Figure 5(b)) at all 
concentrations. As a secondary measure of response to drug 
treatment, the size of cellular aggregates was measured after 
treatment and compared to untreated controls (Figure 5(c)). 
A dose-dependent decrease in the size of cellular aggregates 
broadly correlated with cetuximab treatment efficacy as 
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measured by alamarBlue. The size of HT29 cellular aggre-
gates reduced by up to 35% in size (p < 0.05) when treated 
with 3.4 nM cetuximab compared to untreated controls, 
while the size of HCT116 cellular aggregates remained 
largely unaffected by treatment at any concentration.
Discussion
Classical 2D monolayer culture provides us with a 
medium to explore basic mechanistic investigations into 
cancer cell behaviour in vitro. However, the simplicity 
of this system does not recapitulate cell–cell and cell–
matrix interactions found within the tumour architecture 
that regulates key tumourigenic pathways.17 The emer-
gence of 3D in vitro cancer models aims to address these 
issues by providing a more biomimetic environment for 
cancer cells. To create our 3D model, we chose collagen 
type I as our basic matrix component. Collagen type I 
hydrogels are particularly useful because they are highly 
biocompatible, malleable by cell behaviour and mimic 
Figure 2. Growth kinetics of HT29 and HCT116 cells in 3D culture. (a) The proliferation profile of HT29 and HCT116 colorectal 
cancer cells cultured in 3D over a 14-day period measured by the alamarBlue assay and (b) morphological analysis of HT29 and 
HCT116 3D cultures over a 14-day period. Single cells are seeded and migrate together over time to form cellular aggregates (scale 
bar – 50 µm).
3D: three-dimensional.
Figure 3. Immunofluorescent analysis of cytoskeletal proteins 
on colorectal cancer cultures. HT29 and HCT116 cells in 3D 
cultures were maintained for 14 days, fixed and stained for 
tubulin (red) and F-actin (green – phalloidin). Nuclei were 
stained with DAPI (blue) (scale bar – 50 µm).
3D: three-dimensional; DAPI: 4′,6-diamidino-2-phenylindole.
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the basic ECM composition of the natural tumour micro-
environment.18,19 Our previous work reported the devel-
opment and characterization of a model of colorectal 
cancer based on plastic compression of collagen hydro-
gels.20 The model was created with distinct compart-
ments: a plastically compressed collagen gel populated 
by cancer cells which was nested in uncompressed col-
lagen populated with fibroblasts and endothelial cells. 
This manipulation of collagen density for mimicking the 
dense nature of solid tumours was the first use of this 
technique for culturing cancer cells in 3D. The aim of 
this study was to produce and characterize the use of a 
consistent, scaled down 3D model with physiological 
levels of collagen as a potential drug-screening platform 
using two colorectal cancer cell lines and their response 
to EGFR inhibition.
Prior to drug testing, we characterized the growth char-
acteristics of the two chosen colorectal cancer cell lines in 
3D culture. The growth rates of HT29 and HCT116 cul-
tures, as measured by metabolic activity, varied slightly. 
HT29 cultures exhibited a gradual increase in proliferation 
and appeared to plateau between days 10 and 14. 
Morphologically, the cells did not stop increasing in size or 
number between these time points, implying an inability of 
alamarBlue to penetrate into the tight cellular aggregates. 
This problem of transferring 2D end-point assays to 3D 
cell culture has been highlighted before in detail, and cell 
morphology was investigated as a secondary assay of 
growth.21 Equally, HCT116 cultures proliferated well over 
the 14-day period; however, at day 7, the proliferation pro-
file appeared to drop transiently (Figure 2(a)). There was 
no concomitant reduction in the size of cellular aggregates, 
suggesting that the biochemical changes (reflected in the 
alamarBlue readings) may describe a short phase of quies-
cence, which did not affect gross cellular behaviour. HT29 
and HCT116 cultures formed morphologically distinct cel-
lular aggregates. Immunofluorescent staining of tubulin 
and F-actin demonstrated different expression levels for 
both cytoskeletal proteins. HT29 cultures exhibited a 
slightly lower, more heterogeneous level of expression of 
tubulin; however, this may have been an inability of the 
antibody to penetrate into the cellular aggregates (with 
HT29 appearing to form more tightly packed aggregates 
than HCT116). The penetration of antibodies and large 
molecules has always presented a significant issue in both 
in situ tumours and in vitro tissue-like substitutes. Xiang 
et al.22 treated a spheroid model of mesothelioma with a 
fluorescently labelled SS1P immunotoxin antibody and 
monitored penetration over 16 h. The authors reported that 
the penetration of SS1P was limited to the outer periphery 
of the spheroids following 4 h of treatment indicating inad-
equate penetration to the core of the spheroid. The ‘grape-
like’ morphology of HCT116 has been observed before in 
a panel of breast cancer cell lines cultured in 3D.16 The 
authors found that eight out of nine cells that formed a 
grape-like phenotype were isolated from tumour metasta-
ses indicating an acquired ability of these cells to metasta-
size over the course of their evolution. This supports the 
reported invasive behaviour of HCT116 cells in compari-
son to HT29 cultures.23 Furthermore, the immunofluores-
cent images in Figure 3 show the loosely bound morphology 
of HCT116 cells in addition to the cellular protrusions that 
are typically involved in cell motility.24 These migratory 
fronts are classically driven by chemoattractants that stim-
ulate intracellular pathways such as the EGFR pathway. A 
recent study by Patsialou et al.25 demonstrated that mac-
rophage-dependent invasion of breast tumour cells in a 
mouse model was driven by an epidermal growth factor 
(EGF)/colony-stimulating factor-1 (CSF-1) paracrine loop 
between host tumour cells and macrophages.25 The impli-
cation of these protrusions in our 3D model may indicate 
an autocrine signalling pathway involved in the motility of 
HCT116 cells in physiologically relevant collagen gels.
The expression of EGFR has always been taken as a pre-
requisite for cetuximab therapy. HT29 and HCT116 (low 
and high expressing cell lines, respectively) expressions of 
EGFR were compared and shown to be greatly enhanced in 
3D culture in comparison to 2D. The analysis of cetuximab 
therapy in our 3D model has demonstrated that EGFR 
expression levels do not necessarily correlate with cetuxi-
mab efficacy in vitro. This is consistent with findings in the 
literature.26 Wild et al. measured the EGFR expression lev-
els in 11 human carcinoma xenografts and their responses 
to cetuximab therapy. They revealed a very low correlation 
profile between EGFR expression in xenografts and 
response to cetuximab. However, in recent years, it has 
Figure 4. Quantitative RT-PCR analysis of EGFR mRNA 
levels in colorectal cancer cells. HT29 and HCT116 cells 
were cultured for 3 days in either 2D or 3D cultures. RNA 
was extracted and quantified and qPCR was performed using 
G6PDH as a housekeeping gene. Data are presented as the 
mean ± SD.
RT-PCR: reverse transcription polymerase chain reaction; EGFR: 
epidermal growth factor receptor; mRNA: messenger RNA; 2D: two-
dimensional; 3D: three-dimensional; qPCR: quantitative polymerase 
chain reaction; SD: standard deviation.
*p < 0.05; **p < 0.01.
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emerged that KRAS mutant status is a much more effective 
indicator of response to anti-EGFR therapy.27 The HT29 
cell line was chosen for cetuximab treatment in this case for 
its positive EGFR status and wild-type KRAS status and the 
HCT116 cell line for its KRAS mutant status. Although 
cetuximab was effective on HT29 cells in both 2D and 3D, 
its inhibitory effect was limited at high concentrations. This 
could be due to several reasons. First, HT29 cells are a 
BRAF mutant cell line which has been shown previously to 
lack a sufficient clinical response to cetuximab treatment in 
a small cohort of patients.28 Although the precise mecha-
nisms are not fully understood, it is believed that BRAF and 
KRAS mutant status should be taken together as indicators 
of cetuximab efficacy. Second, it has been suggested that 
immune-dependent mechanisms may contribute to an 
increase in the efficacy of cetuximab.29 However, reduced 
efficacy in vitro may also be attributed to the lack of an 
immune component in our current 3D model. Hsu et al. 
demonstrated for the first time in a xenograft model of non-
small cell lung cancer that increased cetuximab-mediated 
toxicity was driven by an immune-dependent mechanism. 
Complement activation leads to complement-dependent 
cytotoxicity which releases anaphylatoxins, such as C5a, 
that increase the recruitment and activation of effector 
cells. Furthermore, the differences between drug response 
in HT29 cells in 2D and 3D can also be attributed to drug 
pharmacokinetics. Similar to the in vivo scenario, our 3D 
model has displayed a level of ‘resistance’ or non-respon-
siveness to chemotherapeutic treatment in comparison to 
2D cultures. The formation of cellular structures over time 
can function to hinder the penetration of large molecules 
such as cetuximab to the cells in the core, mimicking the in 
vivo drug barrier in tissues. Hence, improving the penetra-
tion of large molecules and drugs will be vital to maximiz-
ing the therapeutic potential of these agents. Finally, 
HCT116 cells either in 2D or 3D were resistant to cetuxi-
mab treatment, in line with their KRAS mutant status. 
Interestingly, exposure to cetuximab appeared to promote 
HCT116 growth by modest, not significant amounts. This 
increase is not sufficient to lead us to investigate whether 
Figure 5. The inhibitory effect of cetuximab on colorectal cancer cells cultured in 2D and 3D. (a) HT29 and HCT116 cells were 
cultured in 2D and treated for 48 h with cetuximab. (b) HT29 and HCT116 3D cultures were cultured for 7 days and treated for 
72 h with increasing concentrations of cetuximab. Cetuximab-treated 3D cultures were then fixed and the (c) surface area of 10 
random cellular aggregates was measured using the ImageJ software and calculated as a percentage of the control (n = 4). Data are 
presented as the mean ± SD.
2D: two-dimensional; 3D: three-dimensional; SD: standard deviation.
*p < 0.05; **p < 0.01; ***p < 0.001.
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this is an example of paradoxical activation of the mitogen-
activated protein kinase/extracellular signal-regulated 
kinase (MAPK/ERK) pathway. However, it is interesting 
that no such pattern was observed in 2D HCT116 cultures, 
highlighting potential differences and usefulness of 3D 
models.
The work described here is the first to investigate the 
use of a 3D model of cancer with physiological concentra-
tions of collagen for pharmacological testing. To date, the 
preclinical drug development process has focused mainly 
on the use of monolayer cell culture systems while disre-
garding microenvironmental cues that affect cell behav-
iour, gene expression and drug diffusion. Although use of 
spheroid cultures can address drug diffusion, further incor-
poration of ECM components such as collagen can help 
direct signals that facilitate intracellular cascade events 
between intracellular and extracellular spaces that may 
influence drug distribution. This model can be further 
improved by incorporating other components of the ECM 
and cell types that are localized to the tumour stroma such 
as endothelial cells or fibroblasts.
Conclusion
In this study, we have established the use of our simple 
and consistent tissue-engineered 3D model as a suitable 
drug-screening platform. Cells behave similar to the in 
vivo scenario, forming tumour-like cellular aggregates 
with visible cell–cell junctions in vitro. Furthermore, we 
have established that cetuximab efficacy is significantly 
lower in 3D cultures in comparison to 2D monolayers, 
independent of EGFR expression levels. This signifies the 
increasingly important role of matrix density and cellular 
architecture on drug uptake and distribution. This model 
could be used to further elucidate the biological mecha-
nisms and physical limitations of drug penetration into in 
situ tumours.
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